Get the Stockscreener App
515.44
0.17%
0.88
After Hours:
514.51
-0.93
-0.18%
Vertex Pharmaceuticals Inc stock is traded at $515.44, with a volume of 852.62K.
It is up +0.17% in the last 24 hours and down -2.68% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$514.56
Open:
$522.1
24h Volume:
852.62K
Relative Volume:
0.59
Market Cap:
$130.64B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
30.56
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
-5.62%
1M Performance:
-2.68%
6M Performance:
+4.68%
1Y Performance:
+29.71%
1-Day Range:
$511.81
$522.10
1-Week Range:
$511.81
$535.00
52-Week Range:
$374.17
$560.25
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 81.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.56B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 54.54B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.59B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis - finance.yahoo.com
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Vertex Pharma stock gains analyst support as JPMorgan raises price target - ad-hoc-news.de
VRTX Reinstated by JP Morgan -- Price Target Raised to $560 - GuruFocus
Vertex trades higher after JPM gives bullish rating - TradingView
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher - FXEmpire
Executives On The Move: Vertex Expands Its Leadership Team Following Crinetics Acquisition - insights.citeline.com
Vertex Pharma stock heads into the open after a modest gain - ad-hoc-news.de
Vertex Pharma EVP Jasper van Grunsven files initial beneficial ownership statement - Bitget
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks - finance.yahoo.com
Vertex Pharmaceuticals (VRTX) executive gets 8,682-share stock grant - Stock Titan
Vertex (NASDAQ: VRTX) executive listed as insider with no reported shares - Stock Titan
Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs - Fierce Biotech
Vertex Pharma stock edges near 52-week high as pipeline expansion supports valuation - ad-hoc-news.de
Vertex at Wells Fargo healthcare conference: renal pipeline takes center stage - Investing.com
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex Pharma stock falls as market digests Crinetics deal and valuation risks - ad-hoc-news.de
Anti-kickback law at play, court tells Vertex as it schools HHS - BioWorld News
Where does Vertex Pharmaceuticals (NASDAQ:VRTX) fit within the Healthcare stocks conversation? - Kalkine Media
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution - Seeking Alpha
Vertex Pharma stock heads into the open after a 3.1 percent drop - ad-hoc-news.de
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send? - TradingKey
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock - fool.com
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights - finance.yahoo.com
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals stock edges lower as market digests strong Q2 figures and insider selling - AD HOC NEWS
Vertex shares fall as investors digest Crinetics acquisition and related financing plans - Quiver Quantitative
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - finance.yahoo.com
Could Nasdaq Focus Lift Attention on Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media
Vertex Pharmaceuticals stock steadies near a 52-week high - AD HOC NEWS
David Taylor sold $ VRTX on Aug. 26, 2026 - Quiver Quantitative
Why Vertex stock is sliding today - Wealth Awesome
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Titan with 4.29% Upside and Robust Buy Ratings - DirectorsTalk Interviews
Vertex Pharma stock slips as revenue and EPS stay in view - AD HOC NEWS
Vertex makes some big people moves, completes its largest acquisition - The Boston Globe
Vertex Fertility Aid Plan Would Violate Kickback Law - Law360
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout - Fierce Biotech
Is Vertex Pharmaceuticals (VRTX) Undervalued Following Casgevy’s FDA Label Expansion? - simplywall.st
Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion By Investing.com - Investing.com Canada
Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - fiercebiotech.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ) - Seeking Alpha
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? - Yahoo Finance
Vertex Pharmaceuticals stock hits all-time high at $555.84 By Investing.com - Investing.com Canada
Vertex Pharmaceuticals stock hits all-time high at $555.84 - Investing.com India
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks - Yahoo Finance
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):